These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11075395)

  • 1. [Adoptive immunotherapy: evaluation and perspectives in the treatment of certain cancers].
    Bartholeyns J; Bardot V; Chokri M; Romet-Lemonne JL
    Rev Med Interne; 2000 Oct; 21(10):863-71. PubMed ID: 11075395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of gene therapy in tumor adoptive immunotherapy].
    Wang C; Zhao Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of gene transfer to cellular immunotherapy.
    Terando A; Chang AE
    Surg Oncol Clin N Am; 2002 Jul; 11(3):621-43. PubMed ID: 12487059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and future applications of cellular therapies for cancer.
    Copier J; Bodman-Smith M; Dalgleish A
    Immunotherapy; 2011 Apr; 3(4):507-16. PubMed ID: 21463192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.
    Vreeland TJ; Clifton GT; Herbert GS; Hale DF; Jackson DO; Berry JS; Peoples GE
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1347-1357. PubMed ID: 27323245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.
    Aspord C; Leccia MT; Salameire D; Laurin D; Chaperot L; Charles J; Plumas J
    J Invest Dermatol; 2012 Oct; 132(10):2395-2406. PubMed ID: 22696054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current developments of immunotherapy in the clinic.
    Antonia S; Mulé JJ; Weber JS
    Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular immunotherapy of cancer: an overview and future directions.
    Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
    Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is antigen specificity the key to efficient adoptive T-cell therapy?
    Labarriere N; Khammari A; Lang F; Dreno B
    Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
    Yannelli JR; Wroblewski JM
    Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell vaccines for cancer immunotherapy.
    Timmerman JM; Levy R
    Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations.
    Whiteside TL
    In Vivo; 1991; 5(6):553-9. PubMed ID: 1810438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive T-cell transfer in melanoma.
    Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
    Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
    Yu G; Moudgil T; Cui Z; Mou Y; Wang L; Fox BA; Hu HM
    J Immunother; 2017 Jun; 40(5):155-163. PubMed ID: 28368960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive cell therapy: past, present and future.
    Cohen JE; Merims S; Frank S; Engelstein R; Peretz T; Lotem M
    Immunotherapy; 2017 Jan; 9(2):183-196. PubMed ID: 28128715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
    Strome SE; Krauss JC; Chang AE; Shu S
    J Hematother; 1993; 2(1):63-73. PubMed ID: 7921967
    [No Abstract]   [Full Text] [Related]  

  • 19. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
    Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L
    Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.